PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Malottki K, Barton P, Tsourapas A, et al. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation. Southampton (UK): NIHR Journals Library; 2011 Mar. (Health Technology Assessment, No. 15.14.)

Glossary

American College of Rheumatology (ACR) 20

Defined as a 20% improvement in the counts of the number of tender and swollen joints and at least three items from the following: observer evaluation of overall disease activity; patient evaluation of overall disease activity; patient evaluation of pain; a score of physical disability; and improvements in blood acute phase responses.

ACR50

Defined as a 50% improvement in the counts of the number of tender and swollen joints and at least three items from the following: observer evaluation of overall disease activity; patient evaluation of overall disease activity; patient evaluation of pain; a score of physical disability; and improvements in blood acute phase responses.

ACR70

Defined as a 70% improvement in the counts of the number of tender and swollen joints and at least three items from the following: observer evaluation of overall disease activity; patient evaluation of overall disease activity; patient evaluation of pain; a score of physical disability; and improvements in blood acute phase responses.

Tumour necrosis factor (TNF) inhibitors

Biological agents that block TNF activity.

Health Assessment Questionnaire (HAQ)

The Health Assessment Questionnaire is designed to assess the physical function of patients. Scores range from 0 (no functional impairment) to 3 (most impaired). Details are provided in Appendix 1.

Disease Activity Score (DAS)

The DAS is calculated using a formula that includes counts for tender (53 joints) and swollen joints (44 joints), an evaluation by the patient of general health and blood acute phase response. Scores range from 0 (best) to 10 (most active disease).

DAS28

Disease Activity Score 28, similar to DAS above but using only 28 joints for assessment. Scores range from 0 (best) to 10 (most active disease).

© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...